Press releases
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant improvement in the time to first occurrence of tumour progression or death (progression free survival or PFS) for study patients treated with the multi-tyrosine kinase inhibitor pazopanib, compared to placebo. PALETTE is a randomised, double-blind, placebo controlled Phase III trial in patients with metastatic soft tissue sarcomas (excluding gastrointestinal stromal tumours and adipocytic sarcomas) and was jointly conducted by GlaxoSmithKline and the European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with cancer centres across the world. Use of pazopanib to treat soft tissue sarcomas is investigational and subject to evaluation of benefits and risks by regulatory authorities before being made available for that use.
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD
GSK and Theravance, Inc. today announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with COPD.
GSK forms partnership with three leading NGOs to address shortage of frontline healthcare workers in Least Developed Countries LDCs
- Agreements signed with AMREF, CARE International UK and Save the Children as part of commitment to reinvest 20% of profits in LDCs
GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® belimumab
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Benlysta® (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy.
Young people’s health charity steps forward to claim top accolade and £35,000
Tower Hamlets-based charity, Step Forward, has beaten more than 400 organisations from around the UK to be crowned the overall winner of this year’s GlaxoSmithKline (GSK) IMPACT Awards, run in partnership with health think-tank The King’s Fund. The charity picked up their award and £35,000 prize at a ceremony last night, held at London’s Science Museum.
pharmaceutical industry and university create manchester collaborative centre for inflammation research
GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out w ith an initial investment of £5M from each partner over a three year period.
GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility
Reported sales -10%; underlying sales* +4% EPS before major restructuring* 32.2p (+9%); dividend 16p (+7%)
Regulatory update – GSK and Valeant respond to FDA on ezogabine
GSK and Valeant Pharmaceuticals International, Inc. submitted on 15 April 2011 the response to the U.S. FDA Complete Response letter received on 30 November 2010 for the NDA for ezogabine.
GSK welcomes key agreement to support global preparedness against pandemic influenza
GlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global preparedness for a future influenza pandemic. The agreement establishes the principles of an improved process for influenza virus and benefit-sharing between the WHO GISN (Global Influenza Surveillance Network) and industry.
Regulatory Update - Tyverb® lapatinib
GlaxoSmithKline plc (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Tyverb (lapatinib) in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumours over-express HER2 (ErbB2).
